139 results on '"Robain, M."'
Search Results
2. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
3. Is Cytomegalovirus Infection a Co-Factor in HIV-1 Disease Progression?
4. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
5. Reply to ‘The potential and perils of observational studies’ by M. Buyse et al.
6. Utilisation des données de vie réelle pour estimer l'effet traitement en cancérologie: émulation du protocole de l'essai randomisé E2100 à partir de la base nationale ESME
7. Corrigendum to “De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis” [Eur J Cancer 158 (2021) 181–188]
8. Molecular testing in older patients treated for an advanced or metastatic nonsquamous non-small-cell lung cancer
9. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis
10. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer
11. Traitements de première ligne et prise en charge du cancer broncho-pulmonaire non à petites cellules avancé ou métastatique avec une mutation EGFR–Analyse de la base nationale de données de vie réelle du programme Épidémio-stratégie médico-économique
12. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France
13. Contemporary picture of metastatic breast cancer: Characteristics and outcomes of 22,000 women from the ESME cohort 2008–2016
14. 279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016
15. Facteurs pronostiques de la survie sans progression chez les patientes atteintes d’un cancer du sein métastatique de type RH+/HER2- avant l’avènement des inhibiteurs CDK dans la cohorte nationale ESME
16. Apport des données de vie réelle dans l’évaluation des traitements chez des patientes traitées pour un cancer du sein métastatique
17. Erickson’s practice for crews: What about coping to the situation with zen?
18. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
19. Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer
20. Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database
21. Abstract P5-17-04: Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort
22. SIOG2021-0009* - Molecular testing in older patients treated for an advanced or metastatic nonsquamous non-small-cell lung cancer
23. Prise en charge des patients atteints d’un cancer bronchopulmonaire à petites cellules de stade IV – Analyse de la base nationale de données de vie réelle du programme Épidémio-Stratégie Médico-Économique (ESME)
24. Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort
25. Utilisation du score de propension : application aux données ESME, pour évaluer l’activité de l’Eribuline en pratique réelle chez les patients atteints d’un cancer du sein métastatique
26. Construction de paramètres d’extrapolation des résultats statistiques de la cohorte ESME Sein métastatique – Reconstruction d’une cohorte de patients traités pour un cancer du sein métastatique dans un CLCC à partir de la cohorte Cancer de l’INCa
27. Construction et évaluation d’un substitut de l’indice fonctionnel ECOG (PS), mesure de l’état de santé général du patient au diagnostic du cancer du sein métastatique
28. Addressing the issue of bias in observational studies : Instrumental variable & Quasi-trial in ESME Research program
29. Abstract P5-20-03: Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcome in 2863 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program
30. Abstract P6-14-02: Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program
31. Abstract P6-08-10: Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort
32. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France
33. DIRAC : A finite impulse response direct adaptive controller
34. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
35. 367P - Prognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer
36. Plateforme de données de vie réelle ESME. Constitution d’une liste de sélection exhaustive multi-source
37. 351P - Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort
38. 265P - Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
39. PIN5 HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE
40. A phase II trial of high-dose chemotherapy (HDCT) supported by haematopoietic stem cell transplantation (HSCT) in patients (pts) with disseminated germ-cell tumors (GCTs) failing chemotherapy and with adverse prognostic factors: The TAXIF II protocol
41. Incidence and sexual risk factors of cytomegalovirus seroconversion in HIV-infected subjects. The SEROCO Study Group.
42. Sexual factors associated with cytomegalovirus seropositivity in human immunodeficiency virus-infected men. The Seroco Study Group.
43. HCV quasipecies complexity is related to CD4 cell count and HCV genotype in HIV coinfected patients
44. Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer
45. Bilan de l'investigation de cinq épidémies communautaires de salmonellose, France, 1993–1994
46. Sexual behavior changes and protease inhibitor therapy. SEROCO Study Group.
47. [Reliability and validity of the French version of the first part of the Appropriateness Evaluation Protocol (AEPf): pertinent criteria of hospitalization stay]
48. 4 Oral - Contemporary picture of metastatic breast cancer: Characteristics and outcomes of 22,000 women from the ESME cohort 2008–2016.
49. 90P Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.
50. Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.